Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for mo...

Full description

Bibliographic Details
Main Authors: Celeste M. Boesjes, Liana F. van der Gang, Nicolaas P.A. Zuithoff, Daphne S. Bakker, Lotte S. Spekhorst, Inge Haeck, Marijke Kamsteeg, Marlies de Graaf, Marjolein S. de Bruin-Weller
Format: Article
Language:English
Published: Medical Journals Sweden 2023-02-01
Series:Acta Dermato-Venereologica
Subjects:
atopic dermatitis
daily practice
upadacitinib
patient-reported outcome measure
Janus kinase inhibitor
Online Access:https://medicaljournalssweden.se/actadv/article/view/5243

Internet

https://medicaljournalssweden.se/actadv/article/view/5243

Similar Items